Please login to the form below

Aspen

This page shows the latest Aspen news and features for those working in and with pharma, biotech and healthcare.

BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial

In the ASPEN trial, Brukinsa hit higher rates of CR and VGPR compared to Imbruvica – 28.9% of relapsed or refractory patients compared to 19.8%.

Latest news

Sandoz expands into Japan with €400m Aspen deal

The acquisition will include shares in Aspen Japan K.K. and all associated assets held by AGI. ... The proceeds Aspen gains from the transaction will be used to reduce its debts.
Aspen to pay millions to NHS following drug pricing investigation

In August, Aspen admitted that it had took part in the arrangement, but the other two companies implicated have made no admission. ... This acquisition made Aspen the sole owner of all existing fludrocortisone marketing authorisations in the UK.
Havas Lynx Group scoops nine Golds at PM Society Awards

Other Gold winners included Aspen, Boeringher Ingelheim, Galderma, Johnson &Johnson, Mundipharma, Napp, Novartis, PTC Therapeutics, Shire, Teva, Tillotts Pharma and ViiV. ... Target Award for Corporate Communications: Ogilvy Healthworld for Boehringer
Grünenthal buys Zomig rights as AZ slimming drive continues

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood
EU starts investigation of Aspen's cancer drug pricing

Amid reports of price increases of several hundred per cent. Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid allegations of ... The five generic medicines - chlorambucil,

More from news
Approximately 9 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Strengthening business competition and reducing anti-competitive practices

based on the allegation that Aspen had paid these competitors to not enter the market. ... In a landmark move, and as the direct product of the investigation, Aspen approached the CMA with an unprecedented settlement offer.
A new EU in the making, what lies ahead for pharma?

She has been creative in the way she pushed the boundaries of the treaties with, for example, the pricing investigation over Aspen Pharma.
Deal Watch October 2016

$330m. Neurology 2016. Aspen. 5 anesthetics. $770m royalties. $592m. 1.3. Neurology 2014.
Deal Watch September 2016

Reflecting a long standing business relationship, Aspen paid GSK £180m to acquire Ultiva, Nimbex, Tracrium, Mivacron and Anectinein, plus up to £100m in milestone payments. ... 500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva,
Deal Watch June 2016

Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

Competition from within

Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,
Compliance Hub Ltd

Address:. Aspen Farm. Sheep Lane Woburn. Bedfordshire. MK17 9HD. UK.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Account Director – Creative Healthcare Communications: Competative

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

Healthcare Account Director: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...